IMGN Immunogen Dashboard

ImmunoGen is developing the next generation of antibody-drug conjugates to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, the company aims to disrupt the progression of cancer and offer its patients more good days.

Company profile

Ticker

IMGN

Exchange

NASDAQ

Website

www.immunogen.com

CEO

Mark Enyedy

Incorporated

Massachusetts

Location

Massachusetts

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Allergan • Abbott Laboratories • Teva- Pharmaceutical Industries • Lilly(Eli) & Co • Bristol-Myers Squibb • Viatris • Warner Chilcott ...

Former names

IMMUNOGEN INC

SEC CIK

0000855654

Corporate docs

Articles of Incorporation & Bylaws

IRS number

42726691

IMGN stock data

S&P 500

1M 1Y 2Y 5Y

News

Pro users get this 30m faster

The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs

30 Jul 21

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29)

Recap: Immunogen Q2 Earnings

30 Jul 21

Shares of Immunogen (NASDAQ:IMGN) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share were down 7.14% year over year to ($0.15), which beat the estimate of ($0.18).

Immunogen Q2 EPS $(0.15) Beats $(0.18) Estimate, Sales $16.90M Miss $18.92M Estimate

30 Jul 21

Immunogen (NASDAQ:IMGN) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.18) by 16.67 percent. This is a 7.14 percent decrease over losses of $(0.14) per share from the same

Earnings Scheduled For July 30, 2021

30 Jul 21

The Week Ahead In Biotech: Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More

25 Jul 21

Press releases

Pro users get this 30m faster

ImmunoGen Reports Recent Progress and Second Quarter 2021 Financial Results

30 Jul 21

Compelling Final Data from FORWARD II Study Combining Mirvetuximab Soravtansine with Avastin® in Recurrent Ovarian Cancer, Regardless of Platinum Status, Presented at ASCO Top-line Data from Pivotal SORAYA Trial

ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2021 Operating Results

15 Jul 21

ImmunoGen Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, July

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

1 Jul 21

ImmunoGen Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on June 30, 2021 the compensation committee of the Company's Board of

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

1 Jun 21

ImmunoGen Announces Webcast of Presentation at Upcoming Jefferies Virtual Healthcare Conference

20 May 21

Calendar

30 Jul 21

1 Aug 21

31 Dec 21

Financial summary

Financial statements Chart IMGN financial data

Quarter (USD)	Jun 21	Mar 21	Dec 20	Sep 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 20	Dec 19	Dec 18	Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Immunogen earnings reports.

Cash burn rate (estimated)	Burn method: Change in cash		Burn method: Operating income/loss		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	239.54M	239.54M	239.54M	239.54M	239.54M	239.54M
Cash burn (monthly)	14.53M	(positive/no burn)	9.12M	3.04M	14.63M	9.22M
Cash used (since last report)	15.87M	n/a	9.96M	3.32M	15.97M	10.07M
Cash remaining	223.67M	n/a	229.57M	236.22M	223.56M	229.47M
Runway (months of cash)	15.4	n/a	25.2	77.7	15.3	24.9

Beta Read what these cash burn values mean

Recent insider trades

IMGN insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
30 Jun 21	Renee Lentini	Common Stock	Grant	Aquire A	No	No	5.52	1,683	9.29K	13,831
30 Jun 21	Ryll Thomas	Common Stock	Grant	Aquire A	No	No	5.52	3,849	21.25K	84,714
30 Jun 21	Wingrove Theresa	Common Stock	Grant	Aquire A	No	No	5.52	1,768	9.76K	77,518
30 Jun 21	Enyedy Mark J	Common Stock	Grant	Aquire A	No	No	5.52	3,849	21.25K	432,866
30 Jun 21	Berkenblit Anna	Common Stock	Grant	Aquire A	No	No	5.52	2,062	11.38K	105,401

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q1 2021

IMGN institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

91.1% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	210	205	+2.4%
Opened positions	33	41	-19.5%
Closed positions	28	19	+47.4%
Increased positions	72	56	+28.6%
Reduced positions	68	72	-5.6%

13F shares	Current	Prev Q	Change
Total value	2.34B	1.12B	+110.0%
Total shares	182.24M	172.9M	+5.4%
Total puts	426.1K	465.8K	-8.5%
Total calls	580.5K	451.9K	+28.5%
Total put/call ratio	0.7	1.0	-28.8%

Largest owners	Shares	Value	Change
Wellington Management	19M	$153.93M	-13.9%
Ra Capital Management	18.42M	$149.18M	0.0%
BLK Blackrock	16.31M	$132.07M	+7.6%
Vanguard	14.31M	$115.89M	+1.1%
FMR	13.53M	$109.63M	+7.9%
Redmile	9.69M	$78.47M	-8.0%
Orbimed Advisors	9.13M	$73.97M	+257.6%
STT State Street	9.02M	$73.09M	+2.5%
Clearbridge Advisors	6.11M	$49.48M	-11.4%
AMP Ameriprise Financial	5.6M	$45.32M	+201.2%

Largest transactions	Shares	Bought/sold	Change
Orbimed Advisors	9.13M	+6.58M	+257.6%
AMP Ameriprise Financial	5.6M	+3.74M	+201.2%
Wellington Management	19M	-3.08M	-13.9%
Consonance Capital Management	703.79K	-2.81M	-80.0%
Renaissance Technologies	1.86M	-2.37M	-56.0%
Adage Capital Partners GP, L.L.C.	4.5M	+2.03M	+81.8%
Lombard Odier Asset Management	1.85M	+1.85M	NEW
Compagnie Lombard Odier SCmA	1.85M	+1.85M	NEW
Marshall Wace North America	32.57K	-1.54M	-97.9%
Citadel Advisors	216.48K	-1.52M	-87.5%

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Pfizer • Astrazeneca • Seagen • Glaxosmithkline • Stemline Therapeutics • Sutro Biopharma • Mersana Therapeutics • Kintara Therapeutics • Xenetic Biosciences • Abbvie

Management Discussion

In the second quarter and first half of 2021, total revenues increased $1.9 million and $4.3 million, respectively, compared to the second quarter and first half of 2020, driven by increases in non-cash royalty revenue, partially offset by decreases in license and milestone fees, both of which are discussed further below.
Kadcyla is a marketed ADC resulting from one of our development and commercialization licenses with the Roche Group, through its Genentech unit. We receive royalty reports and payments related to sales of Kadcyla from Roche one quarter in arrears. In the second quarter and first half of 2021, non-cash royalty revenue increased $2.6 million and $5.2 million, respectively, compared to the second quarter and first half of 2020, driven primarily by increases in net sales of Kadcyla due to market expansion. We sold our rights to receive royalty payments on the net sales of Kadcyla through two separate transactions in 2015 and 2019. Following the 2019 transaction, OMERS, the defined benefit pension plan for municipal employees in the Province of Ontario, Canada, is entitled to receive all of these royalties. See further details regarding the royalty obligation in Note E, “Liability Related to Sale of Future Royalties,” to our consolidated financial statements included in this report.
The amount of license and milestone fees we earn is directly related to the number of our collaborators, the advancement of product candidates covered by the agreements with our collaborators, and the overall success in the clinical trials of these product candidates. As such, the amount of license and milestone fees may vary significantly from quarter to quarter and year to year. License and milestone fee revenue decreased $0.7 million in the second quarter of 2021 compared to the second quarter of 2020 and decreased $0.8 million in the first half of 2021 compared to the first half of 2020, primarily due to the recognition of $0.9 million of previously deferred revenue in the second quarter and first half of 2020 related to the right to future technological improvements upon termination by Takeda of its license agreement.

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: compelling, critical, duration, median, oral, PICCOLO, Restated, strategy, upcoming

Removed: acquire, activated, ample, arise, close, closely, compound, conversion, convert, customary, deliver, ensure, entered, equivalent, estimable, governed, indemnification, indenture, monitor, National, performed, Postemployment, prospective, ranging, relating, representing, repurchased, respond, restructure, separating, soravtansine, stated, subsidiary, trademark, transitioning, transportation, Trust, trustee, unpaid, varying, weather, Wilmington, work, worked

From filing 10-Q 2021 Q2